VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ASCO 2022 | Lymphoma highlights at ASCO 2022

Stephen M. Ansell, MD, PhD, Mayo Clinic, Rochester, MN, gives his highlights in the field of lymphoma presented at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting, including the progression-free survival (PFS) results of first-line brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (A+AVD) in pediatric patients. Prof. Ansell additionally talks on racial and socioeconomic disparities in lymphoma care, which can be especially pronounced with the advent of novel and expensive therapies. This interview took place at the ASCO 2022 Annual Meeting in Chicago, IL.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter